论文部分内容阅读
目的观察并分析克唑替尼治疗ALK(间变性淋巴瘤激酶)阳性晚期非小细胞肺癌患者的临床效果。方法选取我院在2014-03-2015-10收治的ALK阳性非小细胞癌肺癌患者53例作为研究对象,将所有患者按照随机法划分为观察组和对照组,其中对照组患者26例,单纯采用培美曲塞进行治疗,观察组患者27例,克唑替尼进行治疗,对两组患者的治疗效果进行观察,并进行比较。结果观察组患者的治疗有效率明显高于对照组,两组比较差异明显具有统计学意义,P<0.05;比较两组患者的毒性反映情况,观察组患者毒性反应明显高于对照组,但两组比较,无明显差异,P>0.05。结论临床上对于ALK阳性非小细胞肺癌患者,采用克唑替尼进行治疗,治疗效果更好,能够促进患者的预后,提升治疗有效率,具有临床推广使用的价值。
Objective To observe and analyze the clinical effect of crizotinib in patients with ALK (anaplastic lymphoma kinase) positive advanced non-small cell lung cancer. Methods Fifty-three patients with ALK-positive non-small cell lung cancer admitted to our hospital from March 2014 to May 2015 were selected as study subjects. All patients were divided into observation group and control group according to randomized method. Among them, 26 patients in control group were simple Pemetrexed for treatment, observation group of patients in 27 cases, crizotinib treatment, the treatment of two groups of patients were observed and compared. Results The therapeutic efficiency of the observation group was significantly higher than that of the control group, the difference between the two groups was statistically significant (P <0.05). Compared with the toxicity of the two groups, the toxicity of the observation group was significantly higher than that of the control group Group comparison, no significant difference, P> 0.05. CONCLUSION: For patients with ALK-positive non-small cell lung cancer, the treatment with crizotinib clinically has better therapeutic effect, which can promote the prognosis of patients and improve the treatment efficiency, and has the clinical value of clinical use.